Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Juan L. Tamargo, Complutense University of Madrid, Spain

*CORRESPONDENCE Emiliano Giovagnoni, egiovagnoni@aboca.it

SPECIALTY SECTION This article was submitted to Substance-Based Medical Devices, a section of the journal Frontiers in Drug Safety and Regulation

RECEIVED 27 September 2022 ACCEPTED 05 October 2022 PUBLISHED 26 October 2022

CITATION

Giovagnoni E (2022), Corrigendum: Substance-based medical devices made of natural substances: An opportunity for therapeutic innovation. *Front. Drug. Saf. Regul.* 2:1054972. doi: 10.3389/fdsfr.2022.1054972

COPYRIGHT

© 2022 Giovagnoni. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Substance-based medical devices made of natural substances: An opportunity for therapeutic innovation

Emiliano Giovagnoni^{1,2}*

¹Confindustria Substance-based Medical Device Group, Roma, Italy, ²Aboca S.p.A, Sansepolcro, Italy

KEYWORDS

substance-based medical device, medical device made of substances, natural substances, innovation, herbal medicines, medical device regulation, mechanism of action, therapeutic effect

A Corrigendum on

Substance-based medical devices made of natural substances: An opportunity for therapeutic innovation

by Giovagnoni E (2022). Front. Drug. Saf. Regul. 2:998114. doi: 10.3389/fdsfr.2022.998114

In the published article, there are some errors in Table 1 as published. One error is the percentage in the second column third line and the other one is the price in the second column last line $(1.50 \in)$, both referred to Italy. The third error is the price in the third column last line $(3.97 \in)$ referred to Poland. Other numerous errors were found in the "France" column, the entire column. The last error is in the caption where the word "total" is missing.

The corrected Table 1 and its caption appear below.

In the published article, there were some errors in the following paragraph that contains data related to Table 1.

The corrections have been made to **Introduction** in the paragraph **Substance-based** *medical device: Market share*, page 03. These sentences previously stated:

"Aggregate data for these five markets indicate that the SBMD sector is worth 2.9 billion euros, equivalent to 270 million units (MAT May 2022 for Germany, MAT April 2022 for the other countries), and has grown +19% vs. +13.5% of the total self-medication sector (including OTC drugs, medical devices, food supplements and homeopathic medicines).

The number of products registered as SBMDs is greater than 8,700, of which over 4,600 have been placed on the market since 2016. This means that the companies involved in the self-medication sector are investing a lot in the development of SBMDs. This is due to the degree of innovation being delivered by these non-pharmacologically acting products as well as the approval of Regulation 2017/745, which has clarified the EU regulatory framework.

SBMDs currently represent 10% of the total self-medication market, with an average price of \in 10.86 vs. \in 7.47 for the total self-medication sector."

TABLE 1 Summary of sales data showing the importance of SBMDs in the total self-medication sector, including food supplements, in some European Union Member States. Source: IQVIA, Sell Out Multichannel Self-Medication Market MAT, April 2022 (* Germany MAT, May 2022).

Market	Italy	Poland	Spain	France	Germany*
SBMD Market value (million €)	1,153 €	301 €	307 €	447 €	956 €
SBMD market units (million)	86	60	26	64	68
SBMD Market share value of self-medication	15.2%	9.5%	11.5%	7.0%	9.6%
SBMD value market Trend (MAT April 2022 vs. MAT April 2021)	+20%	+32%	+24%	+20%	+11%
Total Self-medication value market Trend (MAT April 2022 vs. MAT April 2021)	+13%	+21%	+19%	+10%	+13%
SBMD number of products on the market in April 2022 (launched on the market since 2016)	3,689 (1,994)	1,594 (876)	686 (415)	734 (375)	2,469 (1,239)
SBMD average price (self-medication average price)	13.33 € (12.50 €)	4.97 € (3.98 €)	11.87 € (9.44 €)	7.00 € (4.64 €)	14.09 € (10.53 €)

IQVIA, Sell Out Multichannel Self-Medication Market MAT, April 2022 (*Germany MAT, May 2022).

The corrected sentences appear below

"Aggregate data for these five markets indicate that the SBMD sector is worth 3.2 billion euros, equivalent to 304 million units (MAT May 2022 for Germany, MAT April 2022 for the other countries), and has grown +18% vs. +13.5% of the total self-medication sector (including OTC drugs, medical devices, food supplements and homeopathic medicines). The number of products registered as SBMDs is greater than 9,100, of which about 4,900 have been placed on the market since 2016. This means that the companies involved in the self-medication sector are investing a lot in the development of SBMDs. This is due to the degree of innovation being delivered by these non-pharmacologically acting products as well as the approval of Regulation 2017/745, which has clarified the EU regulatory framework. SBMDs currently represent 11% of the total self-

medication market, with an average price of \in 10.41 vs. \in 7.47 for the total self-medication sector."

The author apologizes for this errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.